PENG block and cryoablation
Phase 3Small molecule
PENG block and cryoablation is one of 33 small molecule programs targeting Hip Fracture. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Hip Fracture
#DrugCompanyPhaseTrials
1Cyklokapron
JJ Molner
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Bayer Aspirin
BayerApproved
Savaysa
Daiichi SankyoApproved
Marcaine
IInnocoll
Approved
Forteo
AAlmaject
Approved
Ultram
WWim Janssens
Approved
Esmeron
FFresenius Kabi USA, LLC
Approved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Monoferric
PPharmacosmos A/S
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PENG block and cryoablation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Minnesota